Pure Global
NCT06152991

Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy

A Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Comparative, Investigator-initiated Clinical Trial to Evaluate the Efficacy of Carnitine Orotate Complex _Godex® in Patients With Nonalcoholic Fatty Liver Disease
Yoon Jun Kim·Phase 3·ClinicalTrials.gov·drugEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention
GODEX
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Yoon Jun Kim
Funder
Seoul National University Hospital
Location
Seoul, South Korea
Timeline & enrollment
Phase
Phase 3
Start date
Sep 25, 2023
End date
Feb 26, 2027
Enrollment
196 participants
Primary outcome

Change in intrahepatic fat content measured by MRI-PDFF

Summary

the purpose of this clinical trial is to assess the efficacy and safety of Orotic Acid
 Carnitine Complex Capsules (Godex®) in comparison to a placebo control group in patients with
 Non-Alcoholic Fatty Liver Disease (NAFLD).

ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06152991
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06152991 through Pure Global AI's free database. This Phase 3 trial is sponsored by Yoon Jun Kim and is currently Enrolling by invitation. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 196 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.